Fig. 4: Treatment with GSDMBNT mRNA@LNPs promotes tumor control in an anti-PD-1-resistant 4T1 breast cancer mouse model. | Nature Communications

Fig. 4: Treatment with GSDMBNT mRNA@LNPs promotes tumor control in an anti-PD-1-resistant 4T1 breast cancer mouse model.

From: mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy

Fig. 4

a 6, 24, and 72 h after a single dose of GSDMBNT mRNA@LNPs (40 μg mRNA), cytokine concentrations were measured in tumor tissue or serum by ELISA. Data are presented as means ± SD (n = 4 mice per group). Statistical significance was calculated using a two-tailed Student’s t test. b Experimental timeline for treatment of 4T1 orthotopic tumor-bearing mice. s.c., subcutaneous; it, intratumoral; ip, intraperitoneal. c Individual growth curves of tumor size for mice treated as indicated. d, e The average tumor growth curves and survival percentages for mice treated as indicated (n = 7 mice per group). Data shown in e are represented as means ± SD. P values were determined by two-tailed unpaired Student’s t test in c, d or by log-rank (Mantel-Cox) test in e. Source data are provided as a Source Data file. Panel b was created with BioRender.com.

Back to article page